FOR UK HEALTHCARE PROFESSIONALS ONLY
For UK Healthcare Professionals Only

Printed From:

QUESTIONS ABOUT NOVEL CORONAVIRUS?
CLICK HERE.

  1. Home
  2. Atopic dermatitis
  3. Atopic dermatitis
  4. Inflammatory pathways

Dysregulation of the Type 2 immune response pathway leads to underlying Type 2 inflammation in AD and other Type 2 inflammatory diseases2–4


Mode of action DUPIXENT

Have questions about how DUPIXENT works?

Find out more

Overview of AD

Find out more about how AD has a continuous inflammation cycle.

Find out more

Connect with representative

Have questions about DUPIXENT?
Get answers from a representative.

Find out more

AD, atopic dermatitis; IFNγ, interferon gamma; IL, interleukin; ILC, innate lymphoid cells; JAK, Janus kinase; NK, natural killer cells; Th, T-helper cells; TNF, tumour necrosis factor.

References

  1. DUPIXENT Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/8553/smpc. Date accessed: July 2021.
  2. Kaiko GE, et al. Immunol. 2008;123:326–338.
  3. Eyerich K & Eyerich S. J Eur Acad. 2017;32:692–703.
  4. Raphael I, et al. Cytokine. 2015;74:5–17.
  5. Schwartz DM, et al. Nat Rev Rheumatol. 2016;12(1):25–36.
  6. Murray PJ. J Immunol. 2007;178(5):2623–2629.
  7. Annunziato F, et al. J Allergy Clin Immunol. 2015;135(3):626–635.
  8. Schleimer R. Annu Rev Pathol. 2017;12:331–357.
  9. Nakayama T, et al. Annu Rev Immunol. 2017;35:53–84.
  10. Coates LC, et al. Semin Arthritis Rheum. 2016;46:291–304.